Other Events ·
Profound Medical enters co-education agreement with Telix to advance PSMA-informed prostate care
PROFProfound Medical Corp.
Profound Medical Corp. entered into a co-education agreement with Telix Pharmaceuticals Limited to educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies and Profound’s MRI-guided TULSA-PRO platform. The collaboration aims to increase physician awareness, support patient selection, and expand access to the TULSA Procedure through scientific meetings, speaker programs, and educational content. Profound plans to develop PSMA-PET–MR image-fusion capabilities for its Treatment Delivery Console software to enhance treatment planning precision. Profound Medical Corp. is a commercial-stage medical device company that develops and markets innovative interventional MRI procedures.